At Purdue Pharma (Canada), we believe in putting patients and the healthcare professionals who serve them at the core of everything we do, and that means acting with integrity in all our business decisions and actions. We act in accordance with both the spirit and the letter of all applicable laws, regulations, codes and policies – whether they are imposed by third parties or by ourselves.
As a proud member of Innovative Medicines Canada, Purdue Pharma (Canada) voluntarily adheres to the Innovative Medicines Canada Code of Ethical Practices. The Code of Ethical Practices is a commitment from Innovative Medicines Canada, and their members, to a relationship based on trust, accountability and transparency, with the health and well-being of patients and all Canadians as the first priority.
Purdue Pharma (Canada) employees also adhere to our own Code of Ethics to help ensure we continue to maintain the highest standards of ethical conduct in all our business activities. Our values guide our decisions and we always strive to do what is right for the patients we serve, the greater public health, our business, our fellow employees and partners.
We also hold our agents, partners and suppliers to the same standards.
Preventing the Diversion & Abuse of Prescription Opioids
The appropriate management of pain and addressing the effects of misuse, abuse and diversion of prescription pain medications are both serious public health issues. Pain affects millions of people each year. Prescription opioid pain medications remain a safe and effective treatment for appropriately selected and monitored patients. Like all medicines, prescription opioid medicines do have risks and unfortunately, misuse and abuse and diversion of pain medications can lead to tragic consequences, including addiction, overdose and death. Risks and warnings, such as those related to addiction, abuse, and misuse, which are associated with all prescription opioids, are outlined in our Health Canada approved Product Monographs.
Purdue Pharma (Canada) is committed to providing resources to support the responsible use of prescription opioids for pain. As part of these efforts, we focus our interactions with healthcare professionals on sharing evidence-based information, including the guidelines the 2017 Guidelines for Opioids for Chronic Non-Cancer Pain. And we remain steadfast in our position that developing and making available opioids with abuse-deterrent/tamper-resistant properties remains an important aspect of a multifaceted and multi-stakeholder solution.
In addition, Purdue Pharma (Canada) produces a product identification pamphlet that is endorsed by the Canadian Pharmacists Association and designated to be a field reference to help groups such as law enforcement officers, other first responders, addiction outreach workers and a range of healthcare providers visually identify prescription opioid analgesics and stimulants that are marketed in Canada. The pamphlet attempts to summarize the marketed tablet/capsule/patch opioid/stimulant products, but is not all inclusive. Positive identification of any drug requires analysis by an authorized laboratory.
Interested agencies can obtain hard copies of the brochure by sending a request to:
Purdue has been an industry advocate of proper storage and safe disposal of prescription medicine. Safe disposal keeps drugs out of the hands of children and other people who might use them inappropriately. It keeps drugs out of landfill sites and water supplies. And it prevents the inadvertent use of unused or expired medications. A proud member of Canada Health Products Stewardship Association (CHPSA), Purdue helps to fund nation-wide programs that ensure safe and effective collection and disposal of prescription medications. Please visit www.healthsteward.ca for more information. Don’t throw it out, visit www.healthsteward.ca